GB2552405B - A combination pharmaceutical composition and methods of treating diabetes and metabolic disorders - Google Patents

A combination pharmaceutical composition and methods of treating diabetes and metabolic disorders

Info

Publication number
GB2552405B
GB2552405B GB1707872.6A GB201707872A GB2552405B GB 2552405 B GB2552405 B GB 2552405B GB 201707872 A GB201707872 A GB 201707872A GB 2552405 B GB2552405 B GB 2552405B
Authority
GB
United Kingdom
Prior art keywords
methods
pharmaceutical composition
metabolic disorders
treating diabetes
combination pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
GB1707872.6A
Other languages
English (en)
Other versions
GB201707872D0 (en
GB2552405A (en
Inventor
Iliich Epshtein Oleg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44899155&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GB2552405(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from RU2010130348/15A external-priority patent/RU2531048C2/ru
Priority claimed from RU2011127051/15A external-priority patent/RU2509572C2/ru
Application filed by Individual filed Critical Individual
Publication of GB201707872D0 publication Critical patent/GB201707872D0/en
Publication of GB2552405A publication Critical patent/GB2552405A/en
Application granted granted Critical
Publication of GB2552405B publication Critical patent/GB2552405B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
GB1707872.6A 2010-07-21 2011-07-15 A combination pharmaceutical composition and methods of treating diabetes and metabolic disorders Expired - Fee Related GB2552405B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
RU2010130348/15A RU2531048C2 (ru) 2010-07-21 2010-07-21 Лекарственное средство для уменьшения резистентности к инсулину и лечения сахарного диабета и способ повышения эффективности лечения сахарного диабета инсулином и/или гипогликемическими препаратами
RU2011127051/15A RU2509572C2 (ru) 2011-07-01 2011-07-01 Лекарственное средство для уменьшения резистентности к инсулину и для лечения сахарного диабета, способ уменьшения резистентности к инсулину, способ лечения сахарного диабета и способ лечения сахарного диабета инсулином и/или гипогликемическими препаратами
GB1302924.4A GB2496799B (en) 2010-07-21 2011-07-15 A combination pharmaceutical composition and methods of treating diabetes and metabolic disorders

Publications (3)

Publication Number Publication Date
GB201707872D0 GB201707872D0 (en) 2017-06-28
GB2552405A GB2552405A (en) 2018-01-24
GB2552405B true GB2552405B (en) 2018-05-30

Family

ID=44899155

Family Applications (2)

Application Number Title Priority Date Filing Date
GB1707872.6A Expired - Fee Related GB2552405B (en) 2010-07-21 2011-07-15 A combination pharmaceutical composition and methods of treating diabetes and metabolic disorders
GB1302924.4A Expired - Fee Related GB2496799B (en) 2010-07-21 2011-07-15 A combination pharmaceutical composition and methods of treating diabetes and metabolic disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
GB1302924.4A Expired - Fee Related GB2496799B (en) 2010-07-21 2011-07-15 A combination pharmaceutical composition and methods of treating diabetes and metabolic disorders

Country Status (30)

Country Link
US (1) US8617555B2 (cg-RX-API-DMAC7.html)
EP (2) EP2595658A2 (cg-RX-API-DMAC7.html)
JP (2) JP2013533268A (cg-RX-API-DMAC7.html)
KR (2) KR20180127515A (cg-RX-API-DMAC7.html)
CN (1) CN103118707A (cg-RX-API-DMAC7.html)
AR (1) AR082312A1 (cg-RX-API-DMAC7.html)
AU (1) AU2011281240B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013001299A2 (cg-RX-API-DMAC7.html)
CA (1) CA2805961A1 (cg-RX-API-DMAC7.html)
CL (1) CL2013000200A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ2013124A3 (cg-RX-API-DMAC7.html)
DE (1) DE112011102396T5 (cg-RX-API-DMAC7.html)
DK (1) DK201370089A (cg-RX-API-DMAC7.html)
EA (1) EA029847B1 (cg-RX-API-DMAC7.html)
EE (1) EE05761B1 (cg-RX-API-DMAC7.html)
ES (1) ES2445846R1 (cg-RX-API-DMAC7.html)
FI (1) FI20135152L (cg-RX-API-DMAC7.html)
FR (1) FR2962913A1 (cg-RX-API-DMAC7.html)
GB (2) GB2552405B (cg-RX-API-DMAC7.html)
IT (1) ITTO20110627A1 (cg-RX-API-DMAC7.html)
LT (1) LT5980B (cg-RX-API-DMAC7.html)
MX (1) MX2013000804A (cg-RX-API-DMAC7.html)
MY (1) MY160979A (cg-RX-API-DMAC7.html)
NO (1) NO20130265A1 (cg-RX-API-DMAC7.html)
NZ (1) NZ606964A (cg-RX-API-DMAC7.html)
PE (1) PE20130815A1 (cg-RX-API-DMAC7.html)
PH (1) PH12013500140A1 (cg-RX-API-DMAC7.html)
SE (1) SE1350212A1 (cg-RX-API-DMAC7.html)
SG (1) SG187578A1 (cg-RX-API-DMAC7.html)
WO (1) WO2012010966A2 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2181297C2 (ru) 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
UA76638C2 (en) 2002-08-02 2006-08-15 Oleh Illich Epshtein Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon
RU2309732C1 (ru) * 2006-03-13 2007-11-10 Олег Ильич Эпштейн Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата
WO2007149010A1 (en) * 2006-06-06 2007-12-27 Oleg Iliich Epshtein Medicinal agent for treating fatness, diabetes, and diseases associated with impaired glucose tolerance
WO2012007845A2 (en) * 2010-07-15 2012-01-19 Oleg Iliich Epshtein A method of increasing the effect of an activated-potentiated form of an antibody
US8637034B2 (en) 2010-07-15 2014-01-28 Oleg I. Epshtein Pharmaceutical compositions comprising activated-potentiated antibodies to interferon-gamma and S100 protein
ES2542042R1 (es) 2010-07-15 2015-10-06 Oleg Iliich Epshtein Composiciones farmacéuticas y uso para preparar un medicamento destinado al tratamiento de la obesidad, los trastornos metabólicos relacionados y la adicción a sustancias psicoactivas
KR20130102542A (ko) * 2010-07-21 2013-09-17 올레그 일리치 엡쉬테인 현기증, 동요병 및 증식형-혈관 이긴장증 치료용 제약학적 복합 조성물 및 치료 방법들
ES2425315R1 (es) * 2010-07-21 2014-09-08 Oleg Iliich Epshtein Composición farmacéutica y su uso para preparar un medicamento destinado al tratamiento sintomático de una enfermedad o afección respiratoria
CN103119061A (zh) 2010-07-21 2013-05-22 奥列格·伊里奇·爱泼斯坦 治疗注意力不足过动症的方法
JP2013537532A (ja) * 2010-08-06 2013-10-03 イリイチ・エプシテイン オレグ 感染性疾患を治療及び予防する組み合わせ医薬組成物及び方法
TWI588153B (zh) * 2012-05-18 2017-06-21 中國醫藥大學 多胜肽、編碼該多胜肽之核酸分子、以及該多胜肽之應用
RU2013111962A (ru) 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем
RU2013111961A (ru) 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1547612A1 (en) * 2002-08-02 2005-06-29 Oleg Iliich Epshtein Medicinal agent and method for curing erectile dysfunction
EP2036574A1 (en) * 2006-06-06 2009-03-18 Oleg Iliich Epshtein Medicinal agent for treating fatness, diabetes, and diseases associated with impaired glucose tolerance

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4311897A (en) 1979-08-28 1982-01-19 Union Carbide Corporation Plasma arc torch and nozzle assembly
US5811437A (en) * 1996-05-21 1998-09-22 Eli Lilly And Company Methods of increasing nitric oxide synthesis
US6150500A (en) * 1996-07-12 2000-11-21 Salerno; John C. Activators of endothelial nitric oxide synthase
WO1999026657A1 (en) * 1997-11-25 1999-06-03 Musc Foundation For Research Development Inhibitors of nitric oxide synthase
US6933272B1 (en) * 1998-09-22 2005-08-23 Erik Helmerhorst Use of non-peptidyl compounds for the treatment of insulin related ailments
RU2181297C2 (ru) * 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
UA76638C2 (en) 2002-08-02 2006-08-15 Oleh Illich Epshtein Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon
UA76641C2 (uk) 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Гомеопатичний лікарський засіб та спосіб лікування захворювань передміхурової залози
AU2003262804A1 (en) * 2002-08-22 2004-03-11 Nutrition 21, Inc. Arginine silicate inositol complex and use thereof
CN101107003B (zh) 2003-03-14 2012-08-08 营养学研究有限公司 用于治疗疼痛和/或炎症的顺势疗法的配剂
MXPA06008180A (es) * 2004-01-20 2006-08-31 Astellas Pharma Inc Metodo para tratar disfuncion erectil.
RU2438707C2 (ru) * 2006-06-06 2012-01-10 Олег Ильич Эпштейн Лекарственное средство для перорального лечения сахарного диабета и других заболеваний, сопровождающихся нарушением толерантности к глюкозе, и способ получения твердой лекарственной формы для пероральной терапии сахарного диабета и других заболеваний, сопровождающихся нарушением толерантности к глюкозе
GB0812019D0 (en) * 2008-07-02 2008-08-06 Asterion Ltd Insulin
WO2012007845A2 (en) * 2010-07-15 2012-01-19 Oleg Iliich Epshtein A method of increasing the effect of an activated-potentiated form of an antibody
US8637034B2 (en) * 2010-07-15 2014-01-28 Oleg I. Epshtein Pharmaceutical compositions comprising activated-potentiated antibodies to interferon-gamma and S100 protein
ES2542042R1 (es) * 2010-07-15 2015-10-06 Oleg Iliich Epshtein Composiciones farmacéuticas y uso para preparar un medicamento destinado al tratamiento de la obesidad, los trastornos metabólicos relacionados y la adicción a sustancias psicoactivas
KR20130102542A (ko) * 2010-07-21 2013-09-17 올레그 일리치 엡쉬테인 현기증, 동요병 및 증식형-혈관 이긴장증 치료용 제약학적 복합 조성물 및 치료 방법들
ES2425315R1 (es) * 2010-07-21 2014-09-08 Oleg Iliich Epshtein Composición farmacéutica y su uso para preparar un medicamento destinado al tratamiento sintomático de una enfermedad o afección respiratoria

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1547612A1 (en) * 2002-08-02 2005-06-29 Oleg Iliich Epshtein Medicinal agent and method for curing erectile dysfunction
EP2036574A1 (en) * 2006-06-06 2009-03-18 Oleg Iliich Epshtein Medicinal agent for treating fatness, diabetes, and diseases associated with impaired glucose tolerance

Also Published As

Publication number Publication date
KR20180127515A (ko) 2018-11-28
EA201300124A1 (ru) 2013-12-30
LT5980B (lt) 2013-12-27
SG187578A1 (en) 2013-03-28
WO2012010966A2 (en) 2012-01-26
CZ2013124A3 (cs) 2013-06-12
PH12013500140A1 (en) 2013-03-11
US20130064824A1 (en) 2013-03-14
KR20130103486A (ko) 2013-09-23
GB2496799A (en) 2013-05-22
MX2013000804A (es) 2013-10-28
JP2013533268A (ja) 2013-08-22
ITTO20110627A1 (it) 2012-01-22
AR082312A1 (es) 2012-11-28
DE112011102396T5 (de) 2013-05-02
GB201707872D0 (en) 2017-06-28
NO20130265A1 (no) 2013-04-18
FR2962913A1 (fr) 2012-01-27
FI20135152A7 (fi) 2013-02-21
EA029847B1 (ru) 2018-05-31
DK201370089A (en) 2013-02-19
CL2013000200A1 (es) 2015-01-23
EE05761B1 (et) 2016-03-15
LT2013018A (lt) 2013-10-25
AU2011281240A1 (en) 2013-03-07
US8617555B2 (en) 2013-12-31
GB2552405A (en) 2018-01-24
JP2016222684A (ja) 2016-12-28
ES2445846R1 (es) 2015-01-02
CA2805961A1 (en) 2012-01-26
SE1350212A1 (sv) 2013-04-22
GB201302924D0 (en) 2013-04-03
ES2445846A2 (es) 2014-03-05
AU2011281240B2 (en) 2016-07-07
EP3693018A1 (en) 2020-08-12
CN103118707A (zh) 2013-05-22
PE20130815A1 (es) 2013-07-18
BR112013001299A2 (pt) 2017-11-21
WO2012010966A3 (en) 2012-03-29
NZ606964A (en) 2015-08-28
EE201300007A (et) 2013-08-15
EP2595658A2 (en) 2013-05-29
GB2496799B (en) 2017-11-22
FI20135152L (fi) 2013-02-21
MY160979A (en) 2017-03-31

Similar Documents

Publication Publication Date Title
GB2496799B (en) A combination pharmaceutical composition and methods of treating diabetes and metabolic disorders
IL274469A (en) Compositions, uses and methods for the treatment of metabolic disorders and diseases
TWI561271B (en) Dose setting mechanism and method of using same
EP2637667A4 (en) IBAT HEMMER FOR THE TREATMENT OF METABOLISM DISEASES AND RELATED ACCIDENTS
EP2542086A4 (en) COMPOUNDS AND ITS THERAPEUTIC USE
IL223286A0 (en) Piperidine derivatives and their use for the treatment of metabolic disorders
EP2925775A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLISM DISEASES AND DRESSINGS
GB201302653D0 (en) Pharmaceutical compositions and methods of treatment
ZA201304822B (en) Azetidine derivatives useful for the treatment of metabolic and inflimmatory diseases
IL223289A0 (en) Treatment of type 2 diabetes
WO2012021287A9 (en) Methods for the treatment and prevention of metabolic disorders
IL225677A0 (en) A mechanism for determining dosage and a method for using it
EP2704702A4 (en) COMPOSITION AND METHOD OF TREATING DIABETES
GB201302656D0 (en) A combination pharmaceutical composition and methods of treating diseases or conditions associated with the cardiovascular system
ZA201205997B (en) Treatment of a metabolic disorder
IL225673A0 (en) A mechanism for determining dosage and a method for using this mechanism
EP2755685A4 (en) TOLL-LIKE RECEPTOR-3 ANTAGONISTS FOR THE TREATMENT OF METABOLISM AND CARDIAC DISEASES
GB201006167D0 (en) Compounds for the treatment of metabolic disorders
EP2402342A4 (en) PHARMACEUTICAL COMPOSITION FOR TREATING TYPE 2 DIABETES
PH12014501052A1 (en) Methods and compositions for the treatment of diabetes and related symptoms
GB201006166D0 (en) Compounds for the treatment of metabolic disorders
ZA201404738B (en) Treatment of type i and type ii diabetes
GB0904271D0 (en) Treatment of diabetes and metabolic syndrome
GB0910904D0 (en) Treatment of diabetes and metabolic syndrome
GB0912906D0 (en) Treatment of diabetes and metabolic syndrome

Legal Events

Date Code Title Description
PCNP Patent ceased through non-payment of renewal fee

Effective date: 20210715